Review recent notable changes in the management strategies for patients with a targeted drug delivery system. Speakers will also discuss safety, efficacy, and best practices when employing intrathecal therapy. Pharmacodynamic risks will be compared with oral analgesics, including the risk of respiratory depression, endocrinopathy, hyperalgesia, and addiction. Systemic opioid cessation will be discussed alongside an appraisal of the economics of utilizing targeted drug delivery in a contemporary pain practice.
Comparison of Intrathecal and Oral Analgesics: Selected Adverse Effects and Efficacy
Michael S. Leong, MD
Intrathecal Drug Delivery: Is Bolus Administration Better than Continuous?
Jason E. Pope, MD
Cost-Effectiveness of Targeted Drug Delivery
Robert Bolash, MD
- Present the current best practice intrathecal treatments.
- Demonstrate cost-effectiveness data about intrathecal therapy compared with conservative multidisciplinary care.
- Select optimal patients for intrathecal therapy and adjust dosages, including tapering off intrathecal medications.
- Ketamine for Pain, Depression, and Post-Traumatic Stress Disorder (PTSD): What Do We Know? (206)
- Neuropathic Pain: Beyond Adjuvants and Opioids: A Look at New and Reemerging Treatments (207)
- Collecting Patient-Reported Outcomes (PROs) to Enhance Your Practice and What the Collected Registry Data Tells Us So Far (210)
- Suicidality and Chronic Pain: Research/Risk Factors and Monitoring/Evaluation/Treatment in the Context of Opioid Tapering (211)
- A Pain in the Rear: Diagnosing and Treating Lumbar Spine and Sacroiliac Complex Pain (212)